TBPMF - Tetra Bio-Pharma's Cannabis Pain Relief Trials Are Well Supported By Clinical Evidence
Image Source: Analytical Cannabis
Company Thesis
Tetra Bio Pharma (OTCQB:TBPMF) is one of the first companies in the marijuana industry to study the potential effects of analgesia with cannabinoids. Currently, TBMPF's leading clinical trials involves CAUMZ and QIXLEEF (9.5% Dry Pellet THC, 2.5% CBD, administered via inhalation) for the adjunctive treatment of pain (along with opioids) in advanced stage cancer patients and in an non-inferiority study for analgesia against fentanyl. Fortunately, there exists ample clinical evidence supporting the use of nabiximols for pain relief, leading to a high probability the company may succeed